https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2024/08/IVORY-trial-team.jpg
1088
1551
cbrcprod
https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2026/06/NIHR-BRC-Cambridge-Navy-Logo-20-years-scaled.png
cbrcprod2024-08-22 12:03:292025-01-10 18:05:00Global spotlight on Cambridge heart trialThe NIHR BRC: Cambridge is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.
Contact Us
NIHR Biomedical Research Centre: Cambridge
Box 277
Hills Road
Cambridge
CB2 0QQ
Tel: 01223 348490
Congrats to @NIHR20 Research Leaders Prizewinners @CambridgeCRF Operations Director Caroline Saunders & @Cambridge_Uni & @CUH_NHS Neurosurgeon Benjamin Davies, who've both won awards for their leadership skills & commitment to patient-centred research: https://bit.ly/4y0HVFx
3
Are you looking for guidance on setting up a clinical trial? Look no further!
The #CTToolkit is an interactive colour-coded routemap that provides guidance on legal and best practice requirements. Bursting with advice, it's a must-see for any aspiring researcher ➡️
The Lung Immune Challenge Study, led by @Akhilesh_Jha (@HLRI_Cambridge), has reached a milestone with the final participant completing the first phase designed to investigate how immune systems respond to viral lung infections.
➡️ https://buff.ly/tXrD5v8
@The_MRC @CambridgeBRC
Learn about two upcoming career development awards that can support you in undertaking short placements in another part of NIHR or a local authority to enhance your research training experience and academic career development.
📅 Join our webinar from 12-1pm on 3 September to














Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
Integration of polygenic and gut metagenomic risk prediction for common diseases
Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study
A novel human iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases
Replacing device-measured sedentary time with physical activity is associated with lower risk of coronary heart disease regardless of genetic risk